Cellosaurus EN (CVCL_2034)

Cell line name EN
Accession CVCL_2034
Resource Identification Initiative To cite this cell line use: EN (RRID:CVCL_2034)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: MD Anderson Cell Lines Project.
Doubling time: ~50-80 hours (DSMZ).
Microsatellite instability: Instable (MSI-low) (Sanger).
Omics: Deep exome analysis.
Omics: DNA methylation analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Disease Endometrial carcinoma (NCIt: C7558)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Female
Category Cancer cell line
STR profile Source(s): Cosmic-CLP; DSMZ; TKG

Markers:
AmelogeninX
CSF1PO12,14
D13S3178,11
D16S53911.1,12 (DSMZ)
11,12 (Cosmic-CLP; TKG)
D5S81812,13
D7S82011
TH016,9
TPOX8,11
vWA14,17
Web pages http://tcpaportal.org/mclp/
Publications

PubMed=12581894; DOI=10.1016/S0165-4608(02)00673-8
Isaka K., Nishi H., Sagawa Y., Nakada T., Osakabe Y., Serizawa H., Ebihara Y., Takayama M.
Establishment of a new human cell line (EN) with TP53 mutation derived from endometrial carcinoma.
Cancer Genet. Cytogenet. 141:20-25(2003)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

Cross-references
Cell line collections DSMZ; ACC-564
TKG; TKG 0665
Cell line databases/resources CCLE; EN_ENDOMETRIUM
Cosmic-CLP; 1240127
GDSC; 1240127
LINCS_LDP; LCL-1495
Biological sample resources BioSample; SAMN03473481
Gene expression databases GEO; GSM887005
GEO; GSM888074
GEO; GSM1669765
Polymorphism and mutation databases Cosmic; 1576453
Cosmic; 1995393
Cosmic; 2030463